Aberrant expression of lymphoid enhancer–binding factor 1 in Hodgkin lymphoma

Ravindran, Aishwarya; Kurtin, Paul J.; King, Rebecca; Yuan, Ji; Feldman, Andrew L.; Rech, Karen L.; McPhail, Ellen D.; Ding, Wei; Shi, Min

doi:10.1016/j.humpath.2022.04.004

Cited by 2 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for the cases of MZL and LPL that underwent examination, all 142 cases of MZL and 50 cases of LPL were found to be negative for LEF1. A recent review examined the expression of LEF1 in a group of 117 Hodgkin lymphomas, which consisted of 66 cases of classic Hodgkin lymphoma (CHL), 27 cases of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), and 24 cases of Richter transformation of CLL/SLL to CHL [ 10 ]. LEF1 expression was detected in the majority of cases involving both Richter transformation of CLL/SLL to CHL in 80% (19 out of 24) and CHLs in 88% (58 out of 66).…”

Section: Reviewmentioning

confidence: 99%

Diagnosing Lymphoma on Core Needle Biopsy and the Challenging Role of Immunohistochemistry

Al-Maghrabi

2023

Cureus

View full text Add to dashboard Cite

Publications and primary literature both describe the latest advancements in immunohistochemical diagnosis of lymphomas. Along with the updated categorizations, the growing reliance on small biopsy samples to assess lymphoma poses a constant difficulty in hematopathology diagnosis and heightens the demand for immunohistochemistry (IHC). This study aimed to provide practicing lymphoma and hematopathologists with an overview of novel immunohistochemical markers and new applications of already established immunohistochemistry markers to be helpful in lymphoma diagnosis, especially in core needle biopsies. The information was sourced from a review of relevant literature and personal experience gained through professional practice. To effectively diagnose and treat hematolymphoid neoplasms, we need to have a comprehensive understanding of the constantly evolving range of immunohistochemistry studies. This article introduced new markers that contribute to our overall knowledge of the disease, diagnosis, and treatment. The addition of these markers might be helpful in supporting the tumor diagnosis on limited sample material obtained from needle biopsies.

show abstract

Section: Reviewmentioning

confidence: 99%

Diagnosing Lymphoma on Core Needle Biopsy and the Challenging Role of Immunohistochemistry

Al-Maghrabi

2023

Cureus

View full text Add to dashboard Cite

show abstract

Updates in Immunohistochemistry for Hematopoietic and Lymphoid Neoplasms

Kavus

Ding

Dhesi

2023

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— In their 2014 article “New Immunohistochemistry for B-cell Lymphoma and Hodgkin Lymphoma,” Zhang and Aguilera reviewed new immunohistochemical markers for B-cell lymphoma and Hodgkin lymphoma and described how to use these markers for correct lymphoma diagnoses, using the 2008 World Health Organization classifications. Recently, the World Health Organization's WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues published 2022 updates, and, in quick sequence, a second group published an alternative International Consensus Classification of myeloid neoplasms, acute leukemias, and mature lymphoid neoplasms. Regardless of the system a hematopathologist chooses to follow, updates in the immunohistochemical diagnosis of disease are described in both publications as well as in the primary literature. In addition to updated classifications, the increasing use of small biopsy samples for the evaluation of lymphadenopathy continues to challenge hematopathology diagnosis and increase the utilization of immunohistochemistry. Objective.— To review new immunohistochemical markers or new uses of previously known immunohistochemical markers in the evaluation of hematolymphoid neoplasia for the practicing hematopathologist. Data Sources.— Data were obtained from a literature review and personal practice experience. Conclusions.— The practicing hematopathologist requires knowledge of the ever-expanding repertoire of immunohistochemistry for the diagnosis and treatment of hematolymphoid neoplasia. New markers presented in this article help to complete our understanding of disease, diagnosis, and management.

show abstract

Aberrant expression of lymphoid enhancer–binding factor 1 in Hodgkin lymphoma

Cited by 2 publications

References 33 publications

Diagnosing Lymphoma on Core Needle Biopsy and the Challenging Role of Immunohistochemistry

Diagnosing Lymphoma on Core Needle Biopsy and the Challenging Role of Immunohistochemistry

Updates in Immunohistochemistry for Hematopoietic and Lymphoid Neoplasms

Contact Info

Product

Resources

About